Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis

References

• Andrews G, Simonella L, Lapsley H, Evidence-based medicine is affordable: the cost-effectiveness of current compared with optimal treatment in rheumatoid and osteoarthritis. J Rheumatol 2006;33:671-80.
   PubMed Web of Science ®Google Scholar
• Bruyere O, Reginster JY. The need for economic evaluation in osteoarthritis. Aging Health 2009;5:591-4.
   Google Scholar
• Ruchlin HS, Insinga RP. A review of health-utility data for osteoarthritis: implications for clinical trial-based evaluation. Pharmacoeconomics 2008;26:925-35.
   PubMed Web of Science ®Google Scholar
• Marshall JK, Pellissier JM, Attard CL, Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. Pharmacoeconomics 2001;19:1039-49.
   PubMed Web of Science ®Google Scholar
• Contreras-Hernandez I, Mould-Quevedo JF, Torres-Gonzalez R, Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors. Cost Eff Resour Alloc 2008;6:21.
   PubMedGoogle Scholar
• Koskinen E, Eskelinen A, Paavolainen P, Comparison of survival and cost-effectiveness between unicondylar arthroplasty and total knee arthroplasty in patients with primary osteoarthritis: a follow-up study of 50,493 knee replacements from the Finnish Arthroplasty Register. Acta Orthop 2008;79:499-507.
   PubMed Web of Science ®Google Scholar
• Soohoo NF, Sharifi H, Kominski G, Cost-effectiveness analysis of unicompartmental knee arthroplasty as an alternative to total knee arthroplasty for unicompartmental osteoarthritis. J Bone Joint Surg Am 2006;88:1975-82.
   PubMedGoogle Scholar
• Moore A, Phillips C, Hunsche E, Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. Pharmacoeconomics 2004;22:643-60.
   PubMed Web of Science ®Google Scholar
• Tavakoli M. Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam. Pharmacoeconomics 2003;21:443-54.
   PubMed Web of Science ®Google Scholar
• Al MJ, Maniadakis N, Grijseels EW, Janssen M. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands. Value Health 2008;11:589-99.
   PubMed Web of Science ®Google Scholar
• Loyd M, Rublee D, Jacobs P. An economic model of long-term use of celecoxib in patients with osteoarthritis. BMC Gastroenterol 2007;7:25.
   PubMed Web of Science ®Google Scholar
• Kamath CC, Kremers HM, Vanness DJ, The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value Health 2003;6:144-57.
   PubMed Web of Science ®Google Scholar
• Bruyere O, Reginster JY. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging 2007;24:573-80.
   PubMed Web of Science ®Google Scholar
• Bruyere O, Burlet N, Delmas PD, Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord 2008;9:165.
   PubMed Web of Science ®Google Scholar
• Zhang W, Moskowitz RW, Nuki G, OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-62.
   PubMed Web of Science ®Google Scholar
• Jordan KM, Arden NK, Doherty M, EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55.
   PubMed Web of Science ®Google Scholar
• Kahan A, Uebelhart D, De Vathaire F, Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009;60:524-33.
   PubMed Web of Science ®Google Scholar
• Grootendorst P, Marshall D, Pericak D, A model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the knee. J Rheumatol 2007;34:534-42.
   PubMed Web of Science ®Google Scholar
• Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. Br Med J 2001;323:1300-3.
   PubMed Web of Science ®Google Scholar
• Bruyere O, Honore A, Rovati LC, Radiologic features poorly predict clinical outcomes in knee osteoarthritis. Scand J Rheumatol 2002;31:13-16.
   PubMed Web of Science ®Google Scholar
• Dieppe PA. Why is there such a poor correlation between radiographic joint damage and both symptoms and functional impairment in osteoarthritis? Br J Rheumatol 1989;28:242.
   PubMedGoogle Scholar
• Duncan R, Peat G, Thomas E, Symptoms and radiographic osteoarthritis: not as discordant as they are made out to be? Ann Rheum Dis 2007;66:86-91.
   PubMed Web of Science ®Google Scholar
• Pattrick M, Hamilton E, Wilson R, Association of radiographic changes of osteoarthritis, symptoms, and synovial fluid particles in 300 knees. Ann Rheum Dis 1993;52:97-103.
   PubMed Web of Science ®Google Scholar
• Cicuttini FM, Jones G, Forbes A, Rate of cartilage loss at two years predicts subsequent total knee arthroplasty: a prospective study. Ann Rheum Dis 2004;63:1124-7.
   PubMed Web of Science ®Google Scholar
• Bruyere O, Richy F, Reginster JY. Three year joint space narrowing predicts long term incidence of knee surgery in patients with osteoarthritis: an eight year prospective follow up study. Ann Rheum Dis 2005;64:1727-30.
   PubMed Web of Science ®Google Scholar
• Marshall D, Pericak D, Grootendorst P, Validation of a prediction model to estimate health utilities index Mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the hip. Value Health 2008;11:470-7.
   PubMed Web of Science ®Google Scholar
• Barton GR, Sach TH, Jenkinson C, Do estimates of cost-utility based on the EQ 5D differ from those based on the mapping of utility scores? Health Qual Life Outcomes 2008;6:51.
   PubMed Web of Science ®Google Scholar